Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00187148 · ClinicalTrials.gov registry record · Phase 1

Evaluate Tolerability of a Recombinant DNA HIV-1 Vaccine in Healthy Adults

A Phase 1 study, sponsored by St. Jude Children's Research Hospital.

Completed
Registry status
Phase 1
Development phase
6
Enrollment target

NCT00187148 is a Phase 1 study that has completed, run by St. Jude Children's Research Hospital. The registered enrollment target is 6 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00187148, a Phase 1 study, has completed, sponsored by St. Jude Children's Research Hospital.

COMPLETED
Registry status
Phase 1
Development phase
6 participants
Enrollment target

Study Summary

This protocol will evaluate the safety and tolerability of the vaccine EnvDNA in healthy adults. DNA-based vaccines are being studied for the prevention of human immunodeficiency virus (HIV), malaria and hepatitis. DNA vaccines have been well tolerated in human studies to date. The vaccine that will be tested in this study was made from the information that the virus uses to make a small part of the HIV. This small part is called the envelope or coating around the virus. We hope the body will make an immune response against the HIV envelope coat. Our potential HIV DNA envelope vaccine is called EnvDNA.

Interventions

  • BIOLOGICAL EnvDNA

Trial Details

FieldValue
Enrollment Target 6 participants
Start Date 2005-02
Est. Completion 2009-11
Phase Phase 1

What the Registry Record Tells You About NCT00187148

The ClinicalTrials.gov registry entry for NCT00187148 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Jude Children's Research Hospital, which has 410 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which EnvDNA is the first listed.

NCT00187148 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00187148 about?

NCT00187148 is a clinical study titled "Evaluate Tolerability of a Recombinant DNA HIV-1 Vaccine in Healthy Adults". This protocol will evaluate the safety and tolerability of the vaccine EnvDNA in healthy adults. DNA-based vaccines are being studied for the prevention of human immunodeficiency virus (HIV), malaria and hepatitis. DNA vaccines have been well tolerated in human studies to date. The vaccine that will...

What is the current status of trial NCT00187148?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2005-02. Estimated completion is 2009-11.

What interventions are being tested in trial NCT00187148?

The interventions under investigation include: EnvDNA (BIOLOGICAL).

Who is sponsoring clinical trial NCT00187148?

This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.